Erenumab-aooe

Class: Calcitonin Gene-related Peptide (CGRP) Antagonists
- Anti-Calcitonin Gene-related Peptide Monoclonal Antibodies
- Anti-CGRP Monoclonal Antibodies
- Calcitonin Gene-related Peptide Receptor Antagonists
- CGRP Antagonists
- CGRP Receptor Antagonists
Chemical Name: Disulfide with human monoclonal light chain, anti-(human calcitonin gene-related peptide receptor) (human monoclonal heavy chain) immunoglobulin G, dimer
Molecular Formula: C₆₄₇₂H₉₉₆₄N₁₇₂₈O₂₀₁₈S₅₀
CAS Number: 1582205-90-0
Brands: Aimovig

Medically reviewed by Drugs.com on Mar 25, 2022. Written by ASHP.

Introduction

Antimigraine agent; recombinant fully human IgG₂ monoclonal antibody that targets calcitonin gene-related peptide (CGRP) receptor.

Uses for Erenumab-aooe

Preventive Treatment of Migraine

Preventive treatment of migraine in adults.

Substantially reduces monthly migraine days and acute antimigraine agent-use days in patients with episodic or chronic migraine (with or without aura) when compared with placebo.

The American Headache Society (AHS) states that erenumab and other anti-CGRP monoclonal antibodies offer a number of advantages over some oral migraine preventive therapies, including no need for dosage escalation, rapid onset of therapeutic activity, minimal risk of adverse drug reactions, favorable overall tolerability profiles, and demonstrated efficacy after failure of prior preventive treatments or in combination with oral preventive treatments. However, the potential benefit of using newer therapies such as the anti-CGRP monoclonal antibodies over established therapies should be considered on an individual basis.

AHS has established a criteria for initiating treatment with anti-CGRP monoclonal antibodies based on a balance of cost-effective considerations and access to care; according to this criteria, use of anti-CGRP monoclonal antibodies may be appropriate when patients with migraine are unable to tolerate and/or have an inadequate response to an 8-week trial of at least 2 oral preventive therapies (e.g., topiramate, valproate, β-adrenergic blocking agents, tricyclic antidepressants, selective serotonin- and norepinephrine-reuptake inhibitors).

Erenumab-aooe Dosage and Administration

General

Patient Monitoring

• Monitor patients for hypersensitivity reactions.

• Monitor patients for severe constipation.

• Monitor patients for new-onset or worsening hypertension.

Dispensing and Administration Precautions

• Some packaging components of erenumab-aooe contain dry natural rubber, which may cause allergic reactions in individuals sensitive to latex.

Administration

Administer by sub-Q injection once monthly.

Commercially available in single-dose prefilled auto-injectors (i.e., injection pens) and single-dose prefilled syringes containing 70 or 140 mg of the drug; intended for patient self-administration.

Sub-Q Administration

Administer by sub-Q injection i